CD36 - a plausible modifier of disease phenotype in familial adenomatous polyposis.
Merran HolmesToni ConnorChristopher OldmeadowPeter G PockneyRodney J ScottBente A Talseth-PalmerPublished in: Hereditary cancer in clinical practice (2018)
This study provides evidence for patients belonging to the MCR and AFAP groups harbouring specific genotypes for SNPs in CD36 to initiate screening/treatment for FAP at much earlier (MCR) and much later (AFAP) ages than the norm in today's clinical practice. The findings need to be verified in an independent FAP patient cohort.